Posted on 10/07/2026 7:57:10 PM PDT by nickcarraway
Novel medicines can’t be treated in the same zero-sum way as semiconductors or electric vehicles, where one competitor’s win comes at the expense of the other, says Juliana Liu for Bloomberg Opinion.
As Washington and Beijing tussle for dominance in frontier technologies, there’s one area in which competition shouldn’t preclude collaboration: innovative medicines. Beijing’s latest five-year plan for the biotechnology sector details how the country wants to lead the field globally. Unusually for an industrial blueprint, it comes with numeric targets.
By 2030, Chinese drugmakers are expected to have made a “major leap” in competitiveness with sales of new medications growing 20 per cent annually. Pharmaceutical companies aim to develop at least 25 per cent of the world’s first-in-class medicines, which are drugs that work in an entirely new way to treat a condition. They’re also expected to have originated at least five blockbuster therapies with sales of more than US$1 billion a year.
BETTING ON CHINESE RESEARCH
These ambitions aren’t as farfetched as they might seem. Decades of policy support, including investment in education, have helped turn the country into an increasingly fertile source of innovation from a follower in drug development.
(Excerpt) Read more at channelnewsasia.com ...
|
Click here: to donate by Credit Card Or here: to donate by PayPal Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794 Thank you very much and God bless you. |
Right. Just trust the Chicoms and Indians to make good drugs. No problem here.
And Wuhan “lab leaks”?
Trust your enemies at your peril.
Last I read Chicoms produce 70% of heparin, and ~8 million Americans take it annually.
A whole lot of people would find themselves on the 'front lines' of a real war between the U.S. and China.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.